TEAMSFIN (Two dEcAde extensive Myeloma Study in FINland) will study the evolution of multiple myeloma (MM) treatment over two decades in Finland, as well as report on the recent changes in treatment outcomes relative to population controls and also collect data on the use of novel therapeutics, including ixazomib, at the national level for the first time.
